Podcast

Improving Outcomes for Patients with Psoriatic Arthritis: Integrating a Comprehensive…

Launch Date
05/04/2020
Credit Amount
0.00 Expired
Credit Expires
05/04/2021

Faculty

Alexis Ogdie-Beatty, MD, MSCE
Associate Professor of Medicine and Epidemiology, Perelman School of Medicine, University of Pennsylvania
Director, Penn Psoriatic Arthritis Clinic, Hospital of the University of Pennsylvania, Philadelphia
Alexis Ogdie-Beatty, MD, MSCE

Dr. Alexis Ogdie is Associate Professor of Medicine and Epidemiology at the Perelman School of Medicine, University of Pennsylvania. She is an expert in the care of patients with psoriatic arthritis (PsA) and spondyloarthritis (SpA) and is founder and Director of the Penn Psoriatic Arthritis and SpA Program. Dr. Ogdie completed a Master of Science in Clinical Epidemiology in order to integrate pharmacoepidemiology and observational methodology into studies of PsA. The mission of her research program is to improve outcomes in PsA through patient-centered research aiming to develop personalized medicine strategies for PsA (including adjunct therapies), identify appropriate outcome measures for PsA, and improve early identification of the disease.

Explore By Section
Statement of Need Learning Objectives Financial Support Target Audience Credit Information Disclosure Declaration Additional Formats

Statement of Need

Psoriatic arthritis (PsA), a serious and potentially disabling condition, affects approximately 30% of patients with psoriasis, with the joint involvement often occurring about 10 years after the appearance of skin disease. PsA causes not only physical and functional impairments but also has a negative impact on overall quality of life. While dermatologists have an important role in early detection of PsA, patients often have overlapping treatment needs that require collaborative care between dermatologists and rheumatologists.

Recent U.S. Food and Drug Administration (FDA) approvals of several agents for moderate-to-severe PsA have expanded the treatment armamentarium, and the management paradigm continues to evolve. However, PsA continues to be under-recognized, misdiagnosed, and inadequately treated.

In this CMEOCast podcast, expert faculty focus on the latest evidence on screening patients for PsA, individualizing treatment that considers patient-reported outcomes (PROs), and using patient-centered approaches for care, with the goal of optimizing patient outcomes.

Learning Objectives

At the end of this CME/CE activity, participants should be able to:

  • Employ screening and assessment strategies to diagnose patients with PsA in clinical practice.
  • Integrate clinical evidence for targeted therapies when individualizing treatment for patients with PsA, including their effects on PROs.
  • Implement comprehensive, multidisciplinary, patient-centered approaches to treating PsA, taking into account patient preference and presence of comorbidities.

The following learning objectives pertain only to those requesting CNE or CPE credit:

  • Summarize screening and assessment strategies to diagnose patients with PsA in clinical practice.
  • Describe clinical evidence for targeted therapies when individualizing treatment for patients with PsA, including their effects on PROs.
  • Explain comprehensive, multidisciplinary, patient-centered approaches to treating PsA, taking into account patient preference and presence of comorbidities.

Financial Support

Supported by educational grants from Celgene Corporation and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Target Audience

Dermatologists, rheumatologists, nurse practitioners (NPs), physician associates (PAs), and pharmacists

Credit Information

Physicians (ACCME) 1.0

CME Outfitters, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note to Nurse Practitioners

Nurse Practitioners can apply for AMA PRA Category 1 Credit ™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit ™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Pharmacists/Pharmacy Tech (ACPE) 1.0

This application-based activity is approved for 1.0 contact hour (0.10 CEUs) of continuing pharmacy credit.
Activity UAN: 0376-0000-20-071-H01-P

ABIM MOC 1.0

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Ogdie-Beatty reports that she receives grants from Amgen Inc.; Novartis; and Pfizer Inc. She is a consultant for AbbVie Inc.; Amgen Inc.; Bristol Myers Squibb Company; Celgene Corporation; Corrona; Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; Novartis; and Pfizer Inc. Her husband has received other financial or material support in the form of royalties from Novartis.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

  • Jeffrey Helfand, DO (peer reviewer) has no disclosures to report.
  • Mae Ochoa, RPh (peer reviewer) has no disclosures to report.
  • Poshala Tish Aluwihare, PhD (planning committee) has no disclosures to report.
  • Susan Perry (planning committee) has no disclosures to report.
  • Jan Perez (planning committee) has no disclosures to report.
  • Sharon Tordoff (planning committee) has no disclosures to report.

 

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Additional Formats

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

NOTE: Pharmacist CE Universal Activity Number, Enduring: 0376-0000-20-071-H01-P

 

Questions about this activity?

Call us at (877) CME-PROS or (877) 263-7767.

PD-013-050420-90

Improving Outcomes for Patients with Psoriatic Arthritis: Integrating a Comprehensive…
Event Date: 05/04/2020